<DOC>
	<DOC>NCT02250612</DOC>
	<brief_summary>The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28 treatment days in patients with elevated intraocular pressure.</brief_summary>
	<brief_title>SYL040012, Treatment for Open Angle Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Patients older than 18 years of either sex Good or fair general health as assessed by the investigator. Signed informed consent prior to any clinical trialrelated procedures Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT) Postwashout mean IOP above target range BCVA 1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200) Stable visual field Central corneal thickness 480620 μm Shaffer gonioscopic grade of ≥ 3 (in at least 3 quadrants) in both eyes Pregnant or breastfeeding females Females of childbearing potential not willing to use a medically acceptable contraceptive method Clinically significant systemic disease Changes of systemic medication that could have a substantial effect on IOP Known hypersensitivity to any component of the formulations Unable to comply with the clinical trial requirements Clinically significant abnormalities in laboratory tests Severe visual field defect Any secondary glaucoma Pseudoexfoliation or pigment dispersion component, history of angle closure or narrow angles. IOP ≥ 35 mm Hg in any eye Previous nonlaser glaucoma surgery or glaucoma laser procedures (e.g., laser trabeculoplasty) and refractive surgery Any ocular surgery or laser treatment, cataract extraction or ocular trauma within 6 months prior to Baseline Evidence of ocular infection, inflammation, clinically significant blepharitis or conjunctivitis at baseline (Visit 0), or a history of herpes simplex keratitis Clinically significant ocular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>SYL040012</keyword>
	<keyword>bamosiran</keyword>
	<keyword>siRNA</keyword>
	<keyword>RNAi</keyword>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
</DOC>